Grifols Wins Early FDA OK For SCIg Xembify, Setting Stage For Margin Growth
Executive Summary
Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.